ImpediMed Unveils Strategic Advancements at Bell Potter Conference.

ImpediMed Limited (ASX: IPD) recently presented at the Bell Potter Conference, showcasing its advancements in digital health technology through its flagship SOZO platform. The platform provides multiple FDA-cleared applications, including lymphoedema analysis, heart failure monitoring, and hydration assessment. At the time of writing, the company emphasized its primary focus on Breast Cancer-Related Lymphoedema (BCRL) while highlighting a strategy centered on boosting sales, managing costs, and progressing toward breakeven by July 2025.

ImpediMed’s technology has already achieved widespread adoption, with 73% of the U.S. population covered by payor networks and over 1,000 devices deployed globally. The company also revealed its next steps: expanding oncology applications, entering new markets, and enhancing product capabilities while maintaining quality and integrity. ImpediMed’s innovative approach positions it to set a new standard of care in digital health.

Shaping the future of digital health! 🚀 #DigitalHealth #Innovation #ASX

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com